The November 2, 2011, Letter of Intent deadline is fast approaching for a funding opportunity that enables African researchers to carry out large-scale studies on African populations.
NIDA has reissued its Program Announcements (PAs) soliciting collaborative research proposals by U.S. investigators working with investigators from other countries. The PAs—International Research Collaboration on Drug Abuse and Addiction—will be in effect until January 8, 2015.
Researchers may choose one of three grant programs in response to these broad calls for innovative research proposals: R01, R21, or R03. Priority funding will be given to projects that are collaboratively funded by an agency of the foreign country. Research priority areas include:
NIDA has issued several Program Announcements (PAs) that will accept applications from non-U.S. institutions. PAs identify areas of science that are of increased priority at NIDA. The recent funding opportunities open to non-U.S. institutions include:
The Fogarty International Center (FIC) recently announced two new programs of interest to the drug abuse and addiction research community. FIC’s programs provide funding to perform research and to train researchers in a variety of global health topics. The new programs offer funding to enhance research capacity and to mentor and train early-career health scientists in global health topics.
NIDA and the National Institutes of Health (NIH) have recently issued several funding opportunity announcements of interest to the international drug abuse research community:
NIDA is seeking applications for high-risk/high-impact innovative research relevant to NIDA research priorities in (1) basic and clinical neuroscience; (2) drug discovery for medications development; or (3) genetics research involving genetic model systems or human genetics.
Application Deadlines: May 29, 2013
NIDA has agreed to commit up to $3.5 million in fiscal year 2013 funds to support approximately six R01 awards and $500,000 to support approximately two to three R21 awards.